Status: Recruiting
Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas
RAD3CAR is a phase I study designed to evaluatethe safety of B7-H3-CAR T cells and lymphodepletion in combination with hypofractionated radiation therapy. Primary objective: \- To evaluate the safety of B7-H3-CAR T cell therapy after priming with hypofractionated radiation therapy (HFRT) and lymphodepleting chemotherapy in patients ≤ 21 years of age with relapsed/refractory B7-H3+ sarcomas. Secondary objectives: * To describe the antitumor activity of B7-H3-CAR T cells in combination with HFRT * To determine if B7-H3-CAR T cells traffic to tumor sites after combination treatment with HFRT
Participants needed: 42
Trial details
Phase: Phase 1Age: Up to 21Biological sex: AllType: InterventionalSponsor: St. Jude Children's Research HospitalUpdated: Feb 9, 2026Locations: 1
Eligibility criteria
Age ≤ 21 years old [+36]
Known primary immunodeficiency [+18]